Latest Industry Insights

What benefits can insect protein offer? How are regulatory frameworks impacting innovation in this field? And what can be done to drive further advances? Technology Networks had the pleasure of speaking with Thomas Farrugia, chief executive officer of Beta Bugs Limited, to answer these questions and more.

To learn more about a universal vaccine technology and how the platform could be applied to Alzheimer's disease and other neurological indications, Technology Networks spoke with Roman Kniazev, chief executive officer at Nuravax.

There is an inherent link between academia and industry that rarely gets the acknowledgement it deserves. Hear from a roundtable of PhD students on the impact that the collaborative relationship between academia and industry has on their work and the role that technology plays in the “Science Futures” initiative.

While most psychedelic drugs remain illegal in the United States, ketamine has been legal for use by registered practitioners since the 1960s. With the recent recognition of the compound’s use as an antidepressant, more and more clinics are rolling out ketamine-assisted psychotherapy programs.

Psilocybin – the primary active ingredient in magic mushrooms – is to be studied in a new clinical trial that will test whether the psychedelic compound can help people quit smoking.

Technology Networks spoke with Peter Zipfell to learn more about the Innovation Summits and the key themes that will be explored at the events. In this interview, Peter also shares his thoughts on current trends in analytical technologies and software.

To learn more about the CMU Cloud Lab, the motivation behind the project and the benefits it will bring, Technology Networks spoke to Rebecca Doerge, PhD, dean, Mellon College of Science, Carnegie Mellon University, and Toby Blackburn, head of business development and research, Emerald Cloud Lab.

The ability to detect a tumor earlier, when it is smaller, reduces the impact of surgery and treatment, improving the prognosis for many patients. Dxcover has developed a new spectroscopic liquid biopsy approach that is able to identify brain tumors as small as 0.2 cm³ from a blood sample in as little as fifteen minutes.

This article explores how the expanded use of systematic, collaborative registries should allow the medical device, pharmaceutical and oncology communities to gain additional momentum on the road toward personalized cancer care.

Technology Networks recently spoke with Richard Hague, PolarityTE’s chief executive officer and president, to learn more about the science behind SkinTE and how it could overcome some of the limitations associated with other chronic wound treatments.